finance.yahoo.comJUN 46 min read$ABBVBullishLow

The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains

The S&P 500 was up about 11% entering Tuesday, helped by tech gains amid Iran-war and oil-price concerns and expectations of higher interest rates. The article highlights dividend stocks it says look undervalued: AbbVie (forward P/E 15, dividend yield 3.3%, free cash flow just under $20B), CVS Health (forward P/E 12, yield 2.9%, free cash flow $7.4B vs dividends $3.4B), and Verizon (forward P/E just under 10, yield 5.9%, free cash flow nearly $20B vs annual dividends $11.5B; adjusted earnings gr

AI DeskJune 4, 2026

AI analysishow scoring works →

Relevance

6/10

Novelty

4/10

Actionability

Low

Sentiment · $ABBV

Bullish

Timing

Pre-market/early Tuesday positioning around valuation and dividend appeal.

Market alignment

Aligns with risk-on tech-led S&P strength by offering defensive dividend alternatives.

Why this matters for $ABBV

Bullish valuation framing around forward earnings and dividend coverage; no new company-specific catalyst beyond metrics.

Relevance context

Article argues AbbVie’s forward valuation (forward P/E ~15) and free cash flow (~$20B) support its dividend and growth despite high trailing P/E.

Price-impact prediction

Low near-term impact; could support incremental dip-buying sentiment.

Background

The S&P 500 is described as expensive and resilient amid geopolitical/oil and rate-concern headlines; the article pivots to dividend-stock valuation comparisons.

Why it matters

For ABBV/CVS/VZ, the trading takeaway is mainly valuation + dividend safety framing (forward P/E, free cash flow vs dividends, payout ratios) rather than a new fundamental event.

Market relevance

Valuation-and-dividend thesis may influence income-focused positioning, but lacks a discrete catalyst for a high-conviction trade.

Market effects

Sector

Supports a defensive rotation narrative into healthcare/telecom dividend payers when broad indices look expensive.

Regional

Primarily US equity sentiment; could influence US dividend ETF flows.

Global

Limited direct global linkage; mostly US income/valuation positioning.

Alternative perspectives

Contrarian view

Dividend coverage and forward P/E can look attractive, but the article may underweight duration risk (rates) and sector-specific regulatory/competitive pressures not discussed here.

Overlooked factors

No discussion of near-term catalysts (earnings date, guidance changes, litigation/regulatory updates), and the “bargain” framing depends heavily on forward estimates.

Key entities

company
AbbVie
Dividend-paying pharma company; article cites forward P/E (~15) and free cash flow (~$20B) supporting dividend coverage.
company
CVS Health
Healthcare/insurance/pharmacy operator; article cites improving resilience, free cash flow (~$7.4B) vs dividends (~$3.4B), forward P/E (~12).
company
Verizon Communications
Telecom dividend payer; article cites ~5.9% yield, forward P/E (~10), payout ratio <70%, and adjusted earnings growth (5%-6%).

Read at source ← All news

JUN 12

$CVSLow

CVS Health To Deliver Faster, More Personalized Call Center Care for Millions of Members With Salesforce's Agentforce Health

Salesforce (NYSE:CRM) and CVS Health (NYSE:CVS) said they expanded their collaboration using Salesforce’s Agentforce Health to improve call center interactions for CVS Health’s Aetna and CVS Caremark businesses. The platform will use AI agents and secure data access to help resolve member and provider inquiries faster, supporting about 185 million people served annually and 1.5 million providers.

finanznachrichten.de3 min

JUN 11

$CVSMed

CVS Health: Aetna Launches Aetna Mental Health on Demand To Provide Real Time Access to Care and Ongoing Support

CVS Health’s Aetna said it will launch “Aetna Mental Health On Demand” in January 2027 for members aged 13+, offering real-time access to licensed clinicians via chat, phone or video through the Aetna website. Aetna said clinicians use a single-session intervention model and provide ongoing support. The company also added predictive tools for near real-time care management.

finanznachrichten.de4 min

JUN 10

$CVSMed

CVS Caremark Delivers Affordability and Access to GLP

CVS Health’s CVS Caremark said it will update commercial formularies to expand GLP-1 coverage. According to the company, Zepbound (tirzepatide) will be reintroduced as a preferred option on Oct. 1, 2026, and the “new-to-market” block on Foundayo (orforglipron) will be removed where plans approve coverage, effective June 1, 2026. CVS cited efforts to improve affordability and access for members.

3blmedia.com5 min

JUN 8

$BMYLow

Forget Wall Street’s Ultimate Pharma Value Trap: Here Is a Far Better Stock to Buy Right Now

Bristol Myers Squibb (BMY) trades at a low forward P/E and 4.37% dividend yield, but the article says a generic “cliff” is pressuring results. Revlimid fell 63% to $349 million in Q1 2026; Pomalyst dropped 22% to $513 million; Sprycel fell 58%. Non-GAAP EPS was $1.58 vs. $1.80 a year earlier, and 2026 EPS guidance is $6.05–$6.35. By contrast, AbbVie (ABBV) reported Q1 2026 revenue of $15.0 billion (+12.4%); Skyrizi and Rinvoq grew, offsetting Humira’s 38.6% decline. The article also cites raised

finance.yahoo.com7 min

JUN 5

$TLow

Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here’s What It Would Take

The article examines how much capital a $110,000 dual-income household would need to replace spending with dividend stocks, comparing yield tiers. At 6% it implies about $1.83M; at 10% about $1.1M. It cites AT&T’s 4.5% yield (dividend unchanged since 2022) and Verizon’s 5.8% yield (raised to $0.7075). It notes Altria’s 5.8% yield and 1.30x dividend coverage in 2025, while warning higher yields may be less durable.